AU2010256445B2 - Immunoregulatory peptides and methods of use - Google Patents

Immunoregulatory peptides and methods of use Download PDF

Info

Publication number
AU2010256445B2
AU2010256445B2 AU2010256445A AU2010256445A AU2010256445B2 AU 2010256445 B2 AU2010256445 B2 AU 2010256445B2 AU 2010256445 A AU2010256445 A AU 2010256445A AU 2010256445 A AU2010256445 A AU 2010256445A AU 2010256445 B2 AU2010256445 B2 AU 2010256445B2
Authority
AU
Australia
Prior art keywords
seq
peptide
amino acid
inflammation
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010256445A
Other languages
English (en)
Other versions
AU2010256445A1 (en
Inventor
Steven H. Hefeneider
Sharon L. Mccoy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
13Therapeutics Inc
Original Assignee
13Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 13Therapeutics Inc filed Critical 13Therapeutics Inc
Publication of AU2010256445A1 publication Critical patent/AU2010256445A1/en
Application granted granted Critical
Publication of AU2010256445B2 publication Critical patent/AU2010256445B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/065—Poxviridae, e.g. avipoxvirus
    • C07K14/07—Vaccinia virus; Variola virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010256445A 2009-06-05 2010-06-04 Immunoregulatory peptides and methods of use Ceased AU2010256445B2 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US18445509P 2009-06-05 2009-06-05
US18443809P 2009-06-05 2009-06-05
US61/184,438 2009-06-05
US61/184,455 2009-06-05
US22073809P 2009-06-26 2009-06-26
US22074509P 2009-06-26 2009-06-26
US61/220,745 2009-06-26
US61/220,738 2009-06-26
US25636409P 2009-10-30 2009-10-30
US61/256,364 2009-10-30
PCT/US2010/037443 WO2010141845A2 (en) 2009-06-05 2010-06-04 Immunoregulatory peptides and methods of use

Publications (2)

Publication Number Publication Date
AU2010256445A1 AU2010256445A1 (en) 2011-12-22
AU2010256445B2 true AU2010256445B2 (en) 2015-07-30

Family

ID=43298558

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010256445A Ceased AU2010256445B2 (en) 2009-06-05 2010-06-04 Immunoregulatory peptides and methods of use

Country Status (9)

Country Link
US (5) US8450285B2 (enExample)
EP (1) EP2437772B1 (enExample)
JP (1) JP5797191B2 (enExample)
CN (1) CN102803500B (enExample)
AU (1) AU2010256445B2 (enExample)
CA (1) CA2764164A1 (enExample)
MX (1) MX2011012875A (enExample)
NZ (1) NZ596780A (enExample)
WO (1) WO2010141845A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2437772B1 (en) 2009-06-05 2017-12-06 13Therapeutics, Inc. Immunoregulatory peptides and methods of use
US8580748B2 (en) 2011-04-06 2013-11-12 13Therapeutics, Inc. Peptides for the treatment of hearing
TWI609889B (zh) * 2016-05-11 2018-01-01 偉喬生醫股份有限公司 提升蛋白質遞送至細胞內之效率的蛋白標籤及方法
KR101943978B1 (ko) * 2017-12-28 2019-01-30 주식회사 하이센스바이오 신규한 펩타이드
CN109456390B (zh) * 2018-12-27 2021-11-16 西华师范大学 一种人工合成多肽h-473及其应用
KR20230100729A (ko) * 2020-10-30 2023-07-05 푸단 유니버시티 면역반응 조절 또는 항종양 약물 제조에 있어 itpripl1 조절제의 용도

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1979000515A1 (en) 1978-01-16 1979-08-09 Univ Boston Method of effecting cellular uptake of molecules
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
DK0554284T3 (da) 1990-10-24 1997-01-06 Allelix Biopharma Peptid-baserede hæmmere af Hiv-replikation
CA2094658A1 (en) 1992-04-23 1993-10-24 Martin Sumner-Smith Intracellular delivery of biochemical agents
EP0599303A3 (en) 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate
AU729643B2 (en) 1996-05-01 2001-02-08 Antivirals Inc. Polypeptide conjugates for transporting substances across cell membranes
US6228344B1 (en) 1997-03-13 2001-05-08 Mallinckrodt Inc. Method of measuring physiological function
ES2210761T3 (es) * 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
US6589503B1 (en) * 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US6093417A (en) 1999-01-11 2000-07-25 Advanced Medical Instruments Composition to treat ear disorders
WO2001013957A2 (en) 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US7229961B2 (en) * 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6835713B2 (en) * 2001-02-16 2004-12-28 University Of Pittsburgh Virus derived antimicrobial peptides
EP1385872A4 (en) * 2001-05-11 2004-12-15 Res Dev Foundation NF-KAPPA B ACTIVATOR RECEPTOR INHIBITORS AND USES OF SUCH INHIBITORS
EP1412390A2 (en) * 2001-07-26 2004-04-28 Tanox, Inc. Agents that activate or inhibit toll-like receptor 9
JP2006509724A (ja) * 2002-08-01 2006-03-23 ワイス 炎症及びアポトーシスに関係する方法及び試薬
AU2003264836A1 (en) * 2002-09-05 2004-03-29 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Orthopoxvirus vectors, genes and products thereof
CA2520655A1 (en) 2003-04-08 2004-11-04 Biotempt, B.V. Compositions for mucosal and oral administration comprising hcg fragments
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US7192930B2 (en) * 2004-07-12 2007-03-20 U.S. Department Of Veterans Affairs Method and peptide for regulating cellular activity
TW200719884A (en) 2005-03-10 2007-06-01 3M Innovative Properties Co Methods of treating ear infections
AU2007233116B2 (en) * 2006-03-30 2013-05-09 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
US20080039395A1 (en) 2006-08-07 2008-02-14 United States Government As Represented By The Department Of Veterans Affairs Methods for treating septic shock
WO2009132050A2 (en) 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US8722052B2 (en) * 2008-11-17 2014-05-13 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Vaccinia virus protein A46 peptide and use thereof
EP2437772B1 (en) 2009-06-05 2017-12-06 13Therapeutics, Inc. Immunoregulatory peptides and methods of use
US8580748B2 (en) 2011-04-06 2013-11-12 13Therapeutics, Inc. Peptides for the treatment of hearing

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
McCOY S. L., et al, J. of Immunology, 2005, vol 174, pages 3006-3014 *

Also Published As

Publication number Publication date
US20160250320A1 (en) 2016-09-01
WO2010141845A8 (en) 2011-12-01
JP5797191B2 (ja) 2015-10-21
WO2010141845A2 (en) 2010-12-09
JP2012528891A (ja) 2012-11-15
MX2011012875A (es) 2012-02-28
AU2010256445A1 (en) 2011-12-22
EP2437772A4 (en) 2013-07-10
WO2010141845A9 (en) 2011-06-23
US9974853B2 (en) 2018-05-22
US20130203679A1 (en) 2013-08-08
EP2437772A1 (en) 2012-04-11
US8450285B2 (en) 2013-05-28
CA2764164A1 (en) 2010-12-09
US20100317564A1 (en) 2010-12-16
NZ596780A (en) 2013-04-26
EP2437772B1 (en) 2017-12-06
US20130203683A1 (en) 2013-08-08
US9150616B2 (en) 2015-10-06
US20130210741A1 (en) 2013-08-15
CN102803500B (zh) 2014-11-19
US9187530B2 (en) 2015-11-17
US9150617B2 (en) 2015-10-06
CN102803500A (zh) 2012-11-28

Similar Documents

Publication Publication Date Title
US9974853B2 (en) Immunoregulatory peptides and methods of use
TWI881117B (zh) 用於預防或治療SARS-CoV-2感染的疫苗組成物
US8580748B2 (en) Peptides for the treatment of hearing
US20200231628A1 (en) Novel antimicrobial peptide derived from myxinidin peptide and uses thereof
JP5964233B2 (ja) Ｈｐｖにより惹起される疾患の治療用組成物
US20090028874A1 (en) Synthetic Protein as Tumor-Specific Vaccine
KR20230066318A (ko) 재조합 변형된 섬유모세포 성장 인자 및 이의 치료적 용도
CN118453831A (zh) 一种治疗方法
KR102653532B1 (ko) 수퍼옥시드 디스뮤타제 및 이의 건성안의 예방 또는 치료용 용도
NZ541657A (en) Peptide inhibitors of toxins derived from LL-37
CN102884073B (zh) 用于促进血管生成的肽及其用途
US12371459B2 (en) Antimicrobial peptide derived from Pseudin-2 peptide and uses thereof
CN101878226A (zh) 精氨酸取代的新型合成肽及其应用
CN115942951A (zh) Ngf变体，制备，组合物和治疗用途
KR20220058090A (ko) D614g 변이형 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물
CN103897034B (zh) 一种预防和/或治疗炎症反应的小分子多肽及其应用
CN104861058A (zh) 一类新的具有神经保护功能的多肽
CN104371003A (zh) 预防和治疗炎症的小分子多肽及其应用
CN105017406A (zh) 一类新的具有神经保护功能的多肽
US8933031B2 (en) Polypeptide inhibiting angiogenesis and application thereof
CN116568702A (zh) 具有抗菌活性的人β-酪蛋白肽
JP2023517459A (ja) 眼科用医薬組成物及びその使用
KR20120053627A (ko) 재조합 ｈｐｖ 16형 ｅ6 또는 ｅ7 융합 이뮤노글로불린

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired